Gemcitabine/Platinum Containing Regimens as Preoperative Chemotherapy for Patients With Non Small Cell Lung Cancer
Phase 2
Completed
- Conditions
- Carcinoma, Non Small Cell Lung
- Registration Number
- NCT00191230
- Lead Sponsor
- Eli Lilly and Company
- Brief Summary
To study the efficacy and tolerability of gemcitabine/platinum chemotherapy in non small cell lung cancer
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 70
Inclusion Criteria
- Histologically of cytologically confirmed non small cell lung cancer
- No prior chemotherapy or radiation
- No prior malignancy
Exclusion Criteria
- Pregnant or breastfeeding
- Serious concomitant systemic disorder
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Complete pathological response
- Secondary Outcome Measures
Name Time Method Response rate, disease free survival, toxicity including pulmonary toxicity,operative mortality and quality of life.
Trial Locations
- Locations (1)
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
🇺🇸Chapel Hill, North Carolina, United States